Skip to main content
OpenTrials
Completed

NCT Number: NCT04621409

LEAP2 on Postprandial Glucose Metabolism and Food Intake

The study aim to delineate the effects of the naturally occurring peptide liver-enriched antimicrobial peptide 2 (LEAP-2) on postprandial glucose metabolism and food intake in healthy volunteers. The overall objective is to investigate the physiological importance of LEAP-2 in healthy subjects.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–25 year

Sex eligibility

Male

Study type

Interventional

Phase

Early Phase 1

Primary location

Center for Clinical Metabolic Research

Hellerup, 2900, Denmark

About this study

In a recent study, the molecular phenotype of enteroendocrine cells in the small intestine before and after Roux-en-Y Gastric Bypass (RYGB) surgery in obese individuals was examined. Enteroendocrine cells were identified and isolated from intestinal biopsies and analysed for differentially expressed genes by Illumina High Throughput RNA-sequencing. It was discovered that the gene encoding liver-enriched antimicrobial peptide 2 (LEAP-2), a naturally occurring peptide in humans, was significantly upregulated compared to baseline expression. Interestingly, LEAP-2 was recently shown to antagonize ghrelin function in response to feeding in mice. Moreover, the mature murine LEAP-2 peptide is identical in mice and humans. Thus, LEAP-2 has been identified as an endogenous peptide that may be able to alter feeding behaviour and maintenance of glucose levels during calorie restriction.

The study hypothesis is that LEAP-2 alters postprandial glucose metabolism and decreases appetite as well as food intake in relation to a liquid mixed meal and a standardised ad libitum meal compared with saline (placebo) in healthy subjects.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Caucasian men
  • Age between 18 and 25 years
  • Body mass index between 20-35 kg/m2
  • Informed consent

Exclusion criteria

  • Anaemia (haemoglobin below normal range)
  • Alanine aminotransferase (ALAT) and/or aspartate aminotransferase (ASAT) >2 times normal values) or history of hepatobiliary and/or gastrointestinal disorder(s)
  • Nephropathy (serum creatinine above normal range and/or albuminuria)
  • Allergy or intolerance to ingredients included in the standardised meals
  • First-degree relatives with diabetes and/or glycated haemoglobin (HbA1c) >48 mmol/mol
  • Regular tobacco smoking or use of other nicotine-containing products
  • Any ongoing medication that the investigator evaluates would interfere with trial participation.
  • Any physical or psychological condition that the investigator evaluates would interfere with trial participation including any acute or chronic illnesses

Treatment and study plan

Liver-enriched antimicrobial peptide 2

Biological

IV infusion of LEAP2, approximately 5 hours

Placebo

Biological

IV infusion of saline, approximately 5 hours

Primary outcomes

  1. Food intake

    Time frame: 260 to 290 minutes

    Difference in food intake during an ad libitum meal. Food intake is examined as kilojoules (kJ) and kJ/kg body weight of food eaten during the ad libitum meal.

Secondary outcomes

  1. VAS

    Time frame: -30 to 290 minutes

    Visual analogue scales (VASs) assessing appetite, satiety and hunger sensations (from 0 to 10 cm on a scale = from mimimum to maximum sensation)

  2. Alterations in gastric emptying

    Time frame: -30 to 290 minutes

    Paracetamol concentration in plasma after intake of 1.5 g paracetamol

  3. Plasma insulin levels and beta cell secretion assessed by plasma C-peptide concentration relative to plasma glucose concentration

    Time frame: -30 to 290 minutes

    Plasma insulin levels and beta cell secretion assessed by plasma C-peptide concentration relative to plasma glucose concentration

  4. Plasma/serum concentrations of LEAP-2, acyl-ghrelin as well as other glucose- and appetite-regulating gut hormones

    Time frame: -30 to 290 minutes

    Plasma/serum concentrations of LEAP-2, acyl-ghrelin as well as other glucose- and appetite-regulating gut hormones

  5. Changes in resting energy expenditure (REE)

    Time frame: -30 to 290 minutes

    Changes in resting energy expenditure (REE) measured by indirect calorimetry

  6. Assessment of nitrogen balance and protein breakdown in urine

    Time frame: -30 to 290 minutes

    Urine concentrations of urea for assessment of nitrogen balance and protein breakdown

  7. Triglyceride responses

    Time frame: -30 to 290 minutes

    Plasma triglyceride

  8. Cholesterol responses

    Time frame: -30 to 290 minutes

    Plasma cholesterol

  9. Free fatty acid responses

    Time frame: -30 to 290 minutes

    Plasma free fatty acid

Sponsors and collaborators

Lead sponsor

University Hospital, Gentofte, Copenhagen

Other

Registry information

Official study title

Effects of LEAP-2 on Postprandial Glucose Metabolism and Food Intake

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Nov 9, 2020
Registry last updated
May 26, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.